The Food and Drug Administration approved a groundbreaking new oral drug for pancreatic patients suffering from the most aggressive form of the disease. Daraxonrasib, which targets a mutation in a gene called KRAS, doubled the survival time in patients who participated in the trial.

For more context and news coverage of the most important stories of our day, click here: https://www.nbcnews.com

» Subscribe to NBC News: http://nbcnews.to/SubscribeToNBC
» Subscribe to Here’s the Scoop podcast: https://www.nbcnews.com/heres-the-scoop-daily-podcast
» NBC News App: https://apps.nbcnews.com/mobile
» Breaking News Alerts: https://link.nbcnews.com/join/5cj/breaking-news-signup?cid=sm_npd_nn_yt_bn-clip_190621
» Visit NBCNews.Com: http://nbcnews.to/ReadNBC
» Find NBC News on Facebook: http://nbcnews.to/LikeNBC
» Follow NBC News on Twitter: http://nbcnews.to/FollowNBC
» Follow NBC News on Instagram: http://nbcnews.to/InstaNBC

#medicine #cancer #news